Webinar: Redefining Genome Editing for Therapeutic Manufacturing with STAR-CRISPR™

Join the webinar: Redefining Genome Editing for Therapeutic Manufacturing with STAR-CRISPR™

Wednesday, November 19 | 5 PM CET | 11 AM EST | 8 AM PST

As the cell therapy field advances, developers face an ongoing challenge: achieving precise, efficient, and safe genome edits at manufacturing scale.

Join Dr. Stefan Braam and Dr. Suzanne Snellenberg from Cellistic for an in-depth look at STAR-CRISPR™, a next-generation genome editing technology that combines high on-target precision, multiplex capability, and unmatched genomic stability.

Discover how STAR-CRISPR™ integrates seamlessly into automated, phase-appropriate GMP workflows—accelerating the path from design to pre-master cell bank while ensuring regulatory and genetic assurance.

Highlights of the webinar

• How nuclease architecture shapes editing precision, off-target risk, and manufacturability.

• Comparative data showcasing STAR-CRISPR™ performance versus Cas9 and Cpf1.

• How integrated tools — gRNAffe, CatsOFFinder, and AAsCOT — enable safer, more effective edit design.

• How automation and multiplex editing reduce population doublings to preserve genomic stability and cell safety.

• How phase-appropriate GMP workflows ensure a smooth transition from R&D to pre-master cell bank (pre-MCB).

Who should attend

This session is designed for:

• Cell therapy developers seeking safer, faster paths from edit design to manufacturable cell lines.
• Biotech and biopharma companies evaluating iPSC or allogeneic platforms requiring complex genome edits.
• Process development and CMC leaders aiming to integrate high-efficiency, GMP-ready editing workflows.
• Regulatory and quality professionals focused on genetic integrity, off-target assessment, and FDA compliance.
  
  

Register for the webinar